| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 13 | 2017 | 2603 | 0.490 |
Why?
|
| Neoadjuvant Therapy | 3 | 2013 | 394 | 0.400 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2013 | 1312 | 0.320 |
Why?
|
| Osteosarcoma | 1 | 2011 | 275 | 0.280 |
Why?
|
| Bone Neoplasms | 1 | 2011 | 473 | 0.250 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2013 | 250 | 0.240 |
Why?
|
| Information Dissemination | 3 | 2013 | 195 | 0.240 |
Why?
|
| Genetic Counseling | 2 | 2018 | 236 | 0.200 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2022 | 68 | 0.190 |
Why?
|
| Maximum Tolerated Dose | 1 | 2022 | 174 | 0.190 |
Why?
|
| Genetic Research | 2 | 2013 | 56 | 0.180 |
Why?
|
| Tamoxifen | 3 | 2014 | 349 | 0.180 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 1543 | 0.170 |
Why?
|
| Genomics | 3 | 2013 | 1619 | 0.160 |
Why?
|
| Disclosure | 2 | 2018 | 150 | 0.160 |
Why?
|
| Glutathione Transferase | 2 | 2010 | 147 | 0.140 |
Why?
|
| Oncologists | 1 | 2018 | 32 | 0.140 |
Why?
|
| Neoplasm Staging | 4 | 2017 | 1300 | 0.130 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2017 | 87 | 0.130 |
Why?
|
| Mammography | 1 | 2017 | 124 | 0.120 |
Why?
|
| Informed Consent | 3 | 2013 | 348 | 0.120 |
Why?
|
| Quinazolines | 2 | 2014 | 177 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 628 | 0.120 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 949 | 0.110 |
Why?
|
| Genes, BRCA1 | 2 | 2012 | 59 | 0.110 |
Why?
|
| Genetic Testing | 3 | 2011 | 1100 | 0.110 |
Why?
|
| Genetic Privacy | 2 | 2011 | 43 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2011 | 1276 | 0.110 |
Why?
|
| BRCA1 Protein | 2 | 2012 | 82 | 0.110 |
Why?
|
| Communication | 1 | 2018 | 531 | 0.110 |
Why?
|
| Securin | 1 | 2014 | 4 | 0.100 |
Why?
|
| Exome | 1 | 2018 | 1075 | 0.100 |
Why?
|
| Ultrasonography, Mammary | 1 | 2013 | 31 | 0.100 |
Why?
|
| Radiology Information Systems | 1 | 2013 | 27 | 0.100 |
Why?
|
| Research Subjects | 1 | 2013 | 54 | 0.100 |
Why?
|
| Comprehension | 1 | 2013 | 78 | 0.100 |
Why?
|
| Mastectomy | 1 | 2013 | 75 | 0.100 |
Why?
|
| Brain Neoplasms | 2 | 2014 | 1344 | 0.100 |
Why?
|
| Mental Recall | 1 | 2013 | 138 | 0.090 |
Why?
|
| Mammaplasty | 1 | 2013 | 44 | 0.090 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2014 | 135 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2014 | 2024 | 0.090 |
Why?
|
| ErbB Receptors | 1 | 2014 | 295 | 0.090 |
Why?
|
| Combined Modality Therapy | 2 | 2014 | 1233 | 0.090 |
Why?
|
| Humans | 25 | 2022 | 130422 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2014 | 998 | 0.090 |
Why?
|
| Middle Aged | 12 | 2018 | 28383 | 0.090 |
Why?
|
| Guanine Nucleotide Dissociation Inhibitors | 1 | 2011 | 10 | 0.090 |
Why?
|
| Parents | 1 | 2018 | 1103 | 0.080 |
Why?
|
| Female | 21 | 2017 | 70285 | 0.080 |
Why?
|
| Triazines | 1 | 2010 | 34 | 0.080 |
Why?
|
| Estrogen Antagonists | 1 | 2011 | 92 | 0.080 |
Why?
|
| Mammary Glands, Animal | 1 | 2014 | 448 | 0.080 |
Why?
|
| Limb Salvage | 1 | 2011 | 149 | 0.080 |
Why?
|
| Risk Management | 1 | 2011 | 65 | 0.080 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2010 | 94 | 0.080 |
Why?
|
| Genome, Human | 3 | 2011 | 1322 | 0.080 |
Why?
|
| Histone Deacetylases | 1 | 2011 | 130 | 0.080 |
Why?
|
| Ovarian Neoplasms | 2 | 2011 | 434 | 0.080 |
Why?
|
| Polymorphism, Genetic | 2 | 2010 | 776 | 0.080 |
Why?
|
| Medicine | 1 | 2011 | 100 | 0.080 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2014 | 810 | 0.080 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2014 | 602 | 0.080 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2009 | 125 | 0.070 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2014 | 975 | 0.070 |
Why?
|
| Day Care, Medical | 1 | 2008 | 11 | 0.070 |
Why?
|
| Ethics, Medical | 1 | 2011 | 398 | 0.070 |
Why?
|
| Adult | 10 | 2018 | 31127 | 0.070 |
Why?
|
| Consumer Health Information | 1 | 2009 | 28 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 1227 | 0.070 |
Why?
|
| Heterozygote | 1 | 2011 | 720 | 0.070 |
Why?
|
| Community Participation | 1 | 2009 | 42 | 0.070 |
Why?
|
| Aged | 8 | 2017 | 20894 | 0.070 |
Why?
|
| Receptors, Estrogen | 4 | 2014 | 726 | 0.070 |
Why?
|
| Education, Medical, Graduate | 1 | 2013 | 551 | 0.070 |
Why?
|
| Public Opinion | 1 | 2009 | 63 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2011 | 5186 | 0.070 |
Why?
|
| Birth Weight | 1 | 2010 | 341 | 0.070 |
Why?
|
| Pyrazoles | 1 | 2010 | 357 | 0.070 |
Why?
|
| Estrogen Receptor alpha | 1 | 2011 | 426 | 0.070 |
Why?
|
| Cell Line, Tumor | 5 | 2014 | 3715 | 0.070 |
Why?
|
| Physician's Role | 1 | 2009 | 165 | 0.060 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2010 | 214 | 0.060 |
Why?
|
| Vascular Diseases | 1 | 2008 | 153 | 0.060 |
Why?
|
| Prognosis | 2 | 2017 | 4894 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2011 | 774 | 0.060 |
Why?
|
| Survival Rate | 1 | 2011 | 2131 | 0.060 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2008 | 222 | 0.060 |
Why?
|
| Social Support | 1 | 2009 | 363 | 0.060 |
Why?
|
| Neoplasms | 2 | 2018 | 2944 | 0.060 |
Why?
|
| Mice, Nude | 3 | 2014 | 701 | 0.060 |
Why?
|
| Internet | 1 | 2009 | 418 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 3815 | 0.060 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2008 | 583 | 0.060 |
Why?
|
| DNA Methylation | 1 | 2012 | 1090 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2011 | 559 | 0.060 |
Why?
|
| Health Care Surveys | 3 | 2011 | 277 | 0.060 |
Why?
|
| Decision Making | 3 | 2018 | 687 | 0.060 |
Why?
|
| Cerebellar Neoplasms | 1 | 2008 | 328 | 0.060 |
Why?
|
| Glioma | 1 | 2010 | 522 | 0.060 |
Why?
|
| Young Adult | 4 | 2011 | 9995 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2011 | 5069 | 0.050 |
Why?
|
| Medulloblastoma | 1 | 2008 | 390 | 0.050 |
Why?
|
| Cell Proliferation | 4 | 2014 | 2476 | 0.050 |
Why?
|
| Anemia, Sickle Cell | 1 | 2008 | 325 | 0.050 |
Why?
|
| Kidney Neoplasms | 1 | 2008 | 420 | 0.050 |
Why?
|
| Retrospective Studies | 5 | 2017 | 17614 | 0.050 |
Why?
|
| Hospitals, Pediatric | 1 | 2008 | 802 | 0.050 |
Why?
|
| Adolescent | 5 | 2011 | 20754 | 0.050 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2010 | 850 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2014 | 4674 | 0.050 |
Why?
|
| Confidentiality | 2 | 2013 | 105 | 0.040 |
Why?
|
| Apoptosis | 3 | 2014 | 1842 | 0.040 |
Why?
|
| Lymphatic Metastasis | 2 | 2013 | 427 | 0.040 |
Why?
|
| Random Allocation | 2 | 2014 | 416 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2014 | 833 | 0.040 |
Why?
|
| Male | 9 | 2013 | 64527 | 0.040 |
Why?
|
| Immunoblotting | 2 | 2011 | 293 | 0.040 |
Why?
|
| Mutation | 2 | 2011 | 6131 | 0.040 |
Why?
|
| Gene Silencing | 2 | 2011 | 230 | 0.040 |
Why?
|
| Child | 4 | 2018 | 26165 | 0.040 |
Why?
|
| Transplantation, Heterologous | 2 | 2011 | 257 | 0.040 |
Why?
|
| Physicians | 2 | 2018 | 634 | 0.040 |
Why?
|
| RNA, Small Interfering | 2 | 2011 | 667 | 0.030 |
Why?
|
| Professional-Family Relations | 1 | 2018 | 95 | 0.030 |
Why?
|
| Mice | 5 | 2014 | 18188 | 0.030 |
Why?
|
| Patients | 1 | 2018 | 122 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 3425 | 0.030 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2017 | 70 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2018 | 240 | 0.030 |
Why?
|
| Cell Cycle | 2 | 2009 | 600 | 0.030 |
Why?
|
| Gene Expression Profiling | 2 | 2014 | 1827 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 2298 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 435 | 0.030 |
Why?
|
| Capecitabine | 1 | 2014 | 20 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2014 | 81 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2014 | 132 | 0.030 |
Why?
|
| Chromatids | 1 | 2014 | 32 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 81 | 0.030 |
Why?
|
| Animals | 5 | 2014 | 33892 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2014 | 207 | 0.030 |
Why?
|
| Indoles | 1 | 2014 | 199 | 0.020 |
Why?
|
| Pyrroles | 1 | 2014 | 184 | 0.020 |
Why?
|
| Hospitals, Public | 1 | 2013 | 49 | 0.020 |
Why?
|
| Personal Satisfaction | 1 | 2013 | 103 | 0.020 |
Why?
|
| Trastuzumab | 1 | 2013 | 136 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 900 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 426 | 0.020 |
Why?
|
| Nitriles | 1 | 2013 | 161 | 0.020 |
Why?
|
| Time Factors | 2 | 2014 | 6190 | 0.020 |
Why?
|
| Triazoles | 1 | 2013 | 138 | 0.020 |
Why?
|
| Insurance Coverage | 1 | 2013 | 116 | 0.020 |
Why?
|
| Consent Forms | 1 | 2011 | 22 | 0.020 |
Why?
|
| Estradiol | 1 | 2014 | 470 | 0.020 |
Why?
|
| Texas | 2 | 2011 | 3626 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2013 | 441 | 0.020 |
Why?
|
| Linear Models | 1 | 2013 | 688 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 731 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 759 | 0.020 |
Why?
|
| rho-Specific Guanine Nucleotide Dissociation Inhibitors | 1 | 2011 | 7 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2012 | 286 | 0.020 |
Why?
|
| rho Guanine Nucleotide Dissociation Inhibitor alpha | 1 | 2011 | 9 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2011 | 35 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2011 | 237 | 0.020 |
Why?
|
| Vulnerable Populations | 1 | 2013 | 149 | 0.020 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2011 | 51 | 0.020 |
Why?
|
| Genes, BRCA2 | 1 | 2011 | 48 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2010 | 91 | 0.020 |
Why?
|
| Receptor, Insulin | 1 | 2010 | 63 | 0.020 |
Why?
|
| Taxoids | 1 | 2010 | 72 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2013 | 317 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2011 | 192 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2011 | 104 | 0.020 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2011 | 72 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2011 | 6781 | 0.020 |
Why?
|
| Oligodendroglioma | 1 | 2010 | 26 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2011 | 153 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2010 | 301 | 0.020 |
Why?
|
| Fetal Macrosomia | 1 | 2010 | 20 | 0.020 |
Why?
|
| Plasmids | 1 | 2011 | 451 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2009 | 63 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2011 | 582 | 0.020 |
Why?
|
| Surveys and Questionnaires | 2 | 2011 | 4002 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2011 | 219 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2010 | 417 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 683 | 0.020 |
Why?
|
| Protein Phosphatase 2C | 1 | 2009 | 59 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2010 | 589 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2014 | 895 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2011 | 419 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 1606 | 0.020 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2009 | 110 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 655 | 0.020 |
Why?
|
| Private Sector | 1 | 2009 | 26 | 0.020 |
Why?
|
| Risk | 1 | 2011 | 729 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2009 | 307 | 0.020 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2008 | 19 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2010 | 323 | 0.020 |
Why?
|
| Marketing of Health Services | 1 | 2009 | 25 | 0.020 |
Why?
|
| Access to Information | 1 | 2009 | 46 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2013 | 567 | 0.020 |
Why?
|
| Genes, myc | 1 | 2008 | 95 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2008 | 108 | 0.020 |
Why?
|
| Imidazoles | 1 | 2009 | 219 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 1215 | 0.020 |
Why?
|
| Pyridines | 1 | 2009 | 259 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2009 | 305 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 1587 | 0.020 |
Why?
|
| Syndrome | 1 | 2011 | 1160 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2011 | 1215 | 0.020 |
Why?
|
| Smoking | 1 | 2013 | 923 | 0.020 |
Why?
|
| Transfection | 1 | 2009 | 961 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2008 | 202 | 0.020 |
Why?
|
| Autistic Disorder | 1 | 2011 | 395 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 1607 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2008 | 419 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2010 | 675 | 0.020 |
Why?
|
| Counseling | 1 | 2009 | 237 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2013 | 1676 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2013 | 12860 | 0.020 |
Why?
|
| Leukemia | 1 | 2010 | 373 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 1377 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 2835 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 1399 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 1076 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2014 | 3815 | 0.010 |
Why?
|
| Gestational Age | 1 | 2010 | 1212 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2009 | 726 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2009 | 456 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 1458 | 0.010 |
Why?
|
| Quality of Health Care | 1 | 2008 | 406 | 0.010 |
Why?
|
| Logistic Models | 1 | 2010 | 1799 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2008 | 401 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2009 | 613 | 0.010 |
Why?
|
| Patient Readmission | 1 | 2008 | 429 | 0.010 |
Why?
|
| Research Design | 1 | 2009 | 718 | 0.010 |
Why?
|
| Cognition Disorders | 1 | 2008 | 556 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 4695 | 0.010 |
Why?
|
| Genotype | 1 | 2010 | 2605 | 0.010 |
Why?
|
| Epilepsy | 1 | 2011 | 871 | 0.010 |
Why?
|
| Inpatients | 1 | 2008 | 550 | 0.010 |
Why?
|
| Cell Line | 1 | 2008 | 2579 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2011 | 1838 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 1390 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2010 | 14985 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2010 | 3388 | 0.010 |
Why?
|
| Length of Stay | 1 | 2008 | 1395 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2011 | 3682 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2009 | 907 | 0.010 |
Why?
|
| Kidney | 1 | 2008 | 1283 | 0.010 |
Why?
|
| Phenotype | 1 | 2011 | 4474 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2013 | 3112 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2010 | 8493 | 0.010 |
Why?
|
| Risk Factors | 1 | 2010 | 10942 | 0.010 |
Why?
|
| Infant | 1 | 2010 | 13269 | 0.010 |
Why?
|